33,445 Shares in Pfizer Inc. $PFE Bought by Aster Capital Management DIFC Ltd

Aster Capital Management DIFC Ltd acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 33,445 shares of the biopharmaceutical company’s stock, valued at approximately $833,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. State Street Corp boosted its position in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC boosted its position in Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock worth $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Morgan Stanley boosted its position in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank purchased a new stake in Pfizer during the fourth quarter worth $1,830,986,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Monday, March 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research report on Monday, March 9th. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.82.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s CEO said the company could eventually return to high-single-digit growth, suggesting the business may be stronger than investors expect and improving the long-term growth narrative. Here’s When Pfizer’s CEO Says the Company Might Get Back to Generating High-Single-Digit Growth
• Positive Sentiment: Pfizer’s obesity pipeline got a boost after Phase 2b data for berobenatide showed proof of concept, favorable tolerability, and support for moving into Phase 3, which could add a new growth driver. Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation
• Positive Sentiment: RBC Capital upgraded Pfizer, reinforcing the view that the stock’s dividend and valuation may be attractive relative to peers. Pfizer (PFE) Upgraded at RBC Capital. Here is Why
• Neutral Sentiment: Pfizer is drawing heavy investor search interest and additional research coverage, indicating rising attention but not necessarily a direct fundamental catalyst. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Analyst commentary continues to focus on Pfizer’s discounted valuation, fading COVID revenues, and looming patent expirations, leaving the stock’s longer-term rerating story still uncertain. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?
• Neutral Sentiment: Pfizer was also included in a “Top Research Reports” roundup, which adds visibility but does not appear to change the investment thesis on its own. Top Research Reports for Pfizer, Altria & Newmont Corp.
• Negative Sentiment: Ongoing concerns about patent cliffs and declining legacy COVID-related sales continue to cap enthusiasm for Pfizer’s near-term earnings growth. Is Pfizer’s Discounted Valuation a Buying Opportunity or a Value Trap?

Pfizer Stock Performance

NYSE PFE opened at $26.01 on Tuesday. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The stock has a market cap of $148.24 billion, a price-to-earnings ratio of 19.86 and a beta of 0.34. The business has a fifty day moving average of $26.38 and a 200-day moving average of $26.33. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the firm posted $0.92 earnings per share. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer’s payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.